reviewJournal of Medicinal ChemistryFeb 15, 2016HYBRID OA

An Overview of Severe Acute Respiratory Syndrome–Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy

TPThanigaimalai PillaiyarMMManoj ManickamVNVigneshwaran NamasivayamYHYoshio HayashiSJSang‐Hun Jung

University of Bonn · Chungnam National University · +1 more institution

PubMed
Indexed incrossrefdatacitepubmed

Abstract

Severe acute respiratory syndrome (SARS) is caused by a newly emerged coronavirus that infected more than 8000 individuals and resulted in more than 800 (10-15%) fatalities in 2003. The causative agent of SARS has been identified as a novel human coronavirus (SARS-CoV), and its viral protease, SARS-CoV 3CL(pro), has been shown to be essential for replication and has hence been recognized as a potent drug target for SARS infection. Currently, there is no effective treatment for this epidemic despite the intensive research that has been undertaken since 2003 (over 3500 publications). This perspective focuses on the status of various efficacious anti-SARS-CoV 3CL(pro) chemotherapies discovered during the last 12…

Citation impact

849
total citations
FWCI
2.47
Percentile
100%
References
154
Citations per year

Authors

5

Topics & keywords

Topics
Keywords
  • Peptidomimetic
  • Coronavirus
  • Protease
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
  • Severe acute respiratory syndrome coronavirus
  • Severe acute respiratory syndrome
  • Coronaviridae
  • Virology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding